The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

Expert Review of Anticancer Therapy

Volumn 9, Issue 1, 2009, Pages 51-60

  Vogel, Victor G ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer risk reduction; Chemoprevention; Primary prevention; Raloxifene; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PREVENTION; CANCER RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERPLASIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UTERUS CANCER; VERTEBRA FRACTURE; WEIGHT GAIN; BREAST TUMOR; MIDDLE AGED; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 61449444415     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.1.51     Document Type: Article

References (35)

1. Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clin. Cancer Res. 12, 5010-5013 (2006).
2. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003).
3. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647 (1997).
4. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281, 2189-2197 (1999).
5. Lippman ME, Krueger KA, Eckert S et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants. J. Clin. Oncol. 19, 3111-3116 (2001).
6. Cummings SR, Duong T, Kenyon T et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287, 216-220 (2002).
7. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60 (2), 379-411 (2000).
8. Seeman E, Crans GG, Diez-Perez A et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis International 17(2), 313-316 (2006).
9. Fisher B, Costantino JP, Wickerham L et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
10. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652-1662 (2005)
11. Freedman AN, Graubard BI, Rao SR et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst. 95, 526-532 (2003)
12. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer 2, 537-543 (2002)
13. Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl Cancer Inst. 91, 1829-1846 (1999).
14. Armstrong K, Quitsberg A, Micco E et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch. Intern. Med. 166, 2260-2265 (2006).
15. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282, 637-645 (1999).
16. Vogel VG. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women's Health 3, 139-153 (2007).
17. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 65, 125-134 (2001).
18. Grady D, Ettinger B, Moscarelli E et al. Safety and adverse effects associated with raloxifene: Multiple Outcomes Of Raloxifene Evaluation. Obstet. Gynecol. 104, 837-844 (2004).
19. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96(23), 1751-1761 (2004).
20. Barrett-Connor E, Cauley JA, Kulkarni PM et al. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation MORE) randomized trial. J. Bone Miner. Res. 19, 1270-1275 (2004).
21. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): randomised prevention trial. Lancet 360, 817-823 (2002).
22. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst. 99, 272-282 (2007).
23. Veronesi U, Maisonneuve P, Rotmensz N al. Italian randomized trial among women with hysterectomy: tamoxifen and hormonedependent breast cancer in high-risk women. J. Natl Cancer Inst. 95, 160-165 (2003).
24. Veronesi U, Maisonneuve P, Rotmensz N et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J. Natl Cancer Inst. 99, 727-737 (2007).
25. Vogel VG, Costantino JP, Wickerham DL et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2727-2741 (2006).
26. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
27. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J. Natl Cancer Inst. 93, 334-335 (2001).
28. Land SR, Wickerham DL, Costantino JP et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23), 2742-2751 (2006).
29. Barrett-Connor E, Mosca L, Collins P et al. Raloxifene Use for the Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355(2), 125-137 (2006).
30. Stefanick ML. Risk-benefit profiles of raloxifene for women. N. Engl. J. Med. 355(2), 190-192 (2006).
31. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin. Cancer. Res. 11, S900-S905 2005).
32. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
33. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 2008).
34. Goss PE, Strasser-Weippl K. Aromatase inhibitors for chemoprevention. Best Pract. Res. Clin. Endocrinol. Metab. 18, 113-130 (2004)
35. Lippman ME, Cummings SR, Disch DP et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin. Cancer Res. 12, 5242-5247 (2006).